Skip to main content
Canna~Fangled Abstracts

Cannabidiol alters psychophysiological, craving and anxiety responses in an alcohol cue reactivity task: A cross-over randomized controlled trial

By February 1, 2025February 3rd, 2025No Comments

. 2025 Feb 1.

doi: 10.1111/acer.15514.

Online ahead of print.
Tristan Hurzeler 1 2, Warren Logge 1 2, Joshua Watt 1 2, Ian S McGregor 3, Anastasia Suraev 3 4, Paul S Haber 1 2, Kirsten C Morley 1 2
Affiliations 

Abstract

Background: Preclinical studies have demonstrated that cannabidiol (CBD) reduces alcohol-seeking behaviors and may have potential for managing alcohol use disorder (AUD). In this study, we examined the effects of CBD versus placebo on (i) psychophysiological, craving and anxiety responses to alcohol and appetitive cues; (ii) tolerability measures including cognitive functioning.

Methods: Twenty-two non-treatment-seeking individuals with AUD (DSM-5) participated in a cross-over, double-blind, randomized trial, receiving either 800 mg of CBD or matched placebo over 3 days. A laboratory alcohol cue reactivity task with appetitive control (juice) and alcohol exposures, and subsequent recovery periods to examine regulation of cue-elicited responses after cue-offset (recovery) was completed, with psychophysiological indices of autonomic nervous system activity (skin conductance, high-frequency heart rate variability [HF-HRV]) and self-reported measures (alcohol craving and anxiety). Self-reported scales of sedation and neuropsychological executive function tasks were also completed.

Results: CBD sessions were significantly associated with elevated parasympathetic nervous system (PNS) activity across the task, as indicated by increased HF-HRV. Reductions in self-reported anxiety during cue exposure stages compared to placebo sessions were also evidenced. Reductions in self-reported alcohol craving after cue exposure were seen during CBD sessions only. There were no significant differences between CBD and placebo on executive functioning performance.

Conclusions: In a short-term regimen, CBD appears to modulate PNS activity, reduce cue-elicited anxiety during cue exposure and reduce alcohol craving after cue exposure while not significantly impairing cognition. Large, parallel clinical trials with longer term regimens are now needed to determine the therapeutic potential of CBD in the management of AUD.

Keywords: alcohol use disorder, anxiety, cannabidiol, craving, psychophysiology

PubMed Disclaimer

References

REFERENCES

    1. American Psychiatric Association. (2022) Diagnostic and statistical manual of mental disorders (5th Edition).
    1. Austrich‐Olivares, A., García‐Gutiérrez, M.S., Illescas, L., Gasparyan, A. & Manzanares, J. (2022) Cannabinoid CB1 receptor involvement in the actions of CBD on anxiety and coping behaviors in mice. Pharmaceuticals, 15(4), 473.
    1. Bastien, C.H., Vallieres, A. & Morin, C.M. (2001) Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Medicine, 2(4), 297–307.
    1. Braver, T.S., Cohen, J.D., Nystrom, L.E., Jonides, J., Smith, E.E., & Noll, D.C. (1997) A parametric study of prefrontal cortex involvement in human working memory. Neuroimage, 5(1), 49–62. https://doi.org/10.1006/nimg.1996.0247
    1. Bohn, M.J., Krahn, D.D. & Staehler, B.A. (1995) Development and initial validation of a measure of drinking urges in abstinent alcoholics. Alcoholism: Clinical and Experimental Research, 19(3), 600–606.

LinkOut – more resources

Leave a Reply